Related Experiment Videos

Ménage à trois: Sustained therapeutic anti-tumor immunity requires multiple partners in malignant glioma

Derek A Wainwright1, Maciej S Lesniak1

  • 1The Brain Tumor Center; The University of Chicago Pritzker School of Medicine; Chicago, IL USA.

Oncoimmunology
|July 25, 2014
PubMed

Insights

Inhibiting CTLA-4, PD-L1, and IDO significantly improved survival in mice with brain tumors, supporting a new immunotherapy approach for glioblastoma patients.

Area of Science:

  • Neuro-oncology
  • Cancer immunotherapy

Background:

  • Glioblastoma is a highly aggressive primary brain cancer with limited treatment options.
  • Novel immunotherapies are being investigated to improve patient outcomes.

Purpose of the Study:

  • To evaluate the efficacy of combined immunotherapy targeting CTLA-4, PD-L1, and IDO in a preclinical glioblastoma model.
  • To assess the impact of this combinatorial blockade on survival rates in brain tumor-bearing mice.

Main Methods:

  • A preclinical mouse model of glioblastoma was utilized.
  • Mice received treatment involving the inhibition of cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), programmed death-ligand 1 (PD-L1), and indoleamine 2,3-dioxygenase (IDO).
  • Survival data was meticulously collected and analyzed.

Main Results:

  • Combined inhibition of CTLA-4, PD-L1, and IDO demonstrated a significant survival advantage in mice with brain tumors.
  • This triple-blockade immunotherapy approach showed potent anti-tumor effects in the preclinical setting.

Conclusions:

  • The combination of CTLA-4, PD-L1, and IDO inhibition represents a promising novel immunotherapy strategy for glioblastoma.
  • These preclinical findings strongly support the translation of this approach into early-phase clinical trials for glioblastoma patients.
Keywords:
glioblastomaimmunosuppressionimmunotherapymetabolismtryptophan

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.5K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.6K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K